{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T06:15:40Z","timestamp":1792995340504,"version":"4.5.0"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82160148"],"award-info":[{"award-number":["82160148"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","award":["lzujbky-2023-ct06"],"award-info":[{"award-number":["lzujbky-2023-ct06"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","award":["2023RCXM42"],"award-info":[{"award-number":["2023RCXM42"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","award":["24ZDFA007"],"award-info":[{"award-number":["24ZDFA007"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","award":["CY2024-LC-A01"],"award-info":[{"award-number":["CY2024-LC-A01"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","award":["23JRRA1509"],"award-info":[{"award-number":["23JRRA1509"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cellular Signalling"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.cellsig.2025.112163","type":"journal-article","created":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T00:28:30Z","timestamp":1760056110000},"page":"112163","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["PPP1R14B promotes the progression of prostate cancer by regulating the JAK2\/STAT3\/AR pathway and alters the sensitivity and resistance to enzalutamide"],"prefix":"10.1016","volume":"136","author":[{"given":"Long","family":"Cheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengyu","family":"You","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Longtu","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuai","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongfeng","family":"Lao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenyun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhilong","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.cellsig.2025.112163_bb0005","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA A Cancer J. Clin."},{"issue":"12","key":"10.1016\/j.cellsig.2025.112163_bb0010","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/nrc4016","article-title":"Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer","volume":"15","author":"Watson","year":"2015","journal-title":"Nat. Rev. Cancer"},{"issue":"13","key":"10.1016\/j.cellsig.2025.112163_bb0015","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","article-title":"Increased survival with enzalutamide in prostate cancer after chemotherapy. Cabot RC, Harris NL, Rosenberg ES, et al., eds","volume":"367","author":"Scher","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.cellsig.2025.112163_bb0020","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.eururo.2012.12.029","article-title":"Improved survival in a cohort of trial participants with metastatic castration-resistant prostate cancer demonstrates the need for updated prognostic nomograms","volume":"64","author":"Omlin","year":"2013","journal-title":"Eur. Urol."},{"issue":"2","key":"10.1016\/j.cellsig.2025.112163_bb0025","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.cell.2018.05.036","article-title":"Structural alterations driving castration-resistant prostate cancer revealed by linked-read genome sequencing","volume":"174","author":"Viswanathan","year":"2018","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.cellsig.2025.112163_bb0030","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.eururo.2014.05.005","article-title":"Molecular characterization of enzalutamide-treated bone metastatic castration-resistant prostate cancer","volume":"67","author":"Efstathiou","year":"2015","journal-title":"Eur. Urol."},{"issue":"11","key":"10.1016\/j.cellsig.2025.112163_bb0035","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1056\/NEJMoa1315815","article-title":"AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer","volume":"371","author":"Antonarakis","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.cellsig.2025.112163_bb0040","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1158\/0008-5472.CAN-20-1965","article-title":"KIF15-mediated stabilization of AR and AR-V7 contributes to enzalutamide resistance in prostate cancer","volume":"81","author":"Gao","year":"2021","journal-title":"Cancer Res."},{"issue":"4","key":"10.1016\/j.cellsig.2025.112163_bb0045","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1002\/bies.10069","article-title":"Regulator-driven functional diversification of protein phosphatase-1 in eukaryotic evolution","volume":"24","author":"Ceulemans","year":"2002","journal-title":"BioEssays"},{"issue":"5","key":"10.1016\/j.cellsig.2025.112163_bb0050","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1042\/BST20120094","article-title":"Regulation of protein phosphatase 1 by intrinsically disordered proteins","volume":"40","author":"Choy","year":"2012","journal-title":"Biochem. Soc. Trans."},{"issue":"8","key":"10.1016\/j.cellsig.2025.112163_bb0055","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/nrm3149","article-title":"Phosphatases: providing safe passage through mitotic exit","volume":"12","author":"Wurzenberger","year":"2011","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"8","key":"10.1016\/j.cellsig.2025.112163_bb0060","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.tibs.2010.03.002","article-title":"The extended PP1 toolkit: designed to create specificity","volume":"35","author":"Bollen","year":"2010","journal-title":"Trends Biochem. Sci."},{"issue":"474","key":"10.1016\/j.cellsig.2025.112163_bb0065","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.aag1796","article-title":"Genomics and evolution of protein phosphatases","volume":"10","author":"Chen","year":"2017","journal-title":"Sci. Signal."},{"issue":"9","key":"10.1016\/j.cellsig.2025.112163_bb0070","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1016\/j.ajhg.2024.07.013","article-title":"Evidence-based recommendations for gene-specific ACMG\/AMP variant classification from the ClinGen ENIGMA BRCA1 and BRCA2 variant curation expert panel","volume":"111","author":"Parsons","year":"2024","journal-title":"Am. J. Hum. Genet."},{"issue":"6","key":"10.1016\/j.cellsig.2025.112163_bb0075","doi-asserted-by":"crossref","first-page":"457","DOI":"10.3892\/etm.2024.12747","article-title":"Prognostic value of Ki67 in phyllodes tumor of the breast: a systematic review and meta-analysis","volume":"28","author":"Refai","year":"2024","journal-title":"Exp. Ther. Med."},{"issue":"24","key":"10.1016\/j.cellsig.2025.112163_bb0080","doi-asserted-by":"crossref","first-page":"5905","DOI":"10.1242\/jcs.01506","article-title":"Migration and retraction of endothelial and epithelial cells require PHI-1, a specific protein-phosphatase-1 inhibitor protein","volume":"117","author":"Tountas","year":"2004","journal-title":"J. Cell Sci."},{"issue":"8","key":"10.1016\/j.cellsig.2025.112163_bb0085","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1038\/s41375-023-01951-8","article-title":"The ribosomal protein S6 kinase alpha-1 (RPS6KA1) induces resistance to venetoclax\/azacitidine in acute myeloid leukemia","volume":"37","author":"Weidenauer","year":"2023","journal-title":"Leukemia"},{"key":"10.1016\/j.cellsig.2025.112163_bb0090","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2021.763561","article-title":"PPP1R14B is a prognostic and immunological biomarker in pan-cancer","volume":"12","author":"Deng","year":"2021","journal-title":"Front. Genet."},{"issue":"12","key":"10.1016\/j.cellsig.2025.112163_bb0095","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1010123","article-title":"RSK1 SUMOylation is required for KSHV lytic replication. Krug LT, ed","volume":"17","author":"Liu","year":"2021","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.cellsig.2025.112163_bb0100","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2020.557614","article-title":"LncRNA PPP1R14B-AS1 promotes tumor cell proliferation and migration via the enhancement of mitochondrial respiration","volume":"11","author":"Yang","year":"2020","journal-title":"Front. Genet."},{"issue":"6","key":"10.1016\/j.cellsig.2025.112163_bb0105","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1111\/jcmm.17697","article-title":"PPP1R14B is a diagnostic prognostic marker in patients with uterine corpus endometrial carcinoma","volume":"27","author":"He","year":"2023","journal-title":"J. Cell. Mol. Med."},{"key":"10.1016\/j.cellsig.2025.112163_bb0110","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.1025594","article-title":"Genome-wide association studies identify miRNA-194 as a prognostic biomarker for gastrointestinal cancer by targeting ATP6V1F, PPP1R14B, BTF3L4 and SLC7A5","volume":"12","author":"Huang","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.cellsig.2025.112163_bb0115","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.2147\/OTT.S273264","article-title":"LINC00466 impacts cell proliferation, metastasis and sensitivity to temozolomide of glioma by sponging miR-137 to regulate PPP1R14B expression","volume":"14","author":"Zhao","year":"2021","journal-title":"OTT"},{"key":"10.1016\/j.cellsig.2025.112163_bb0120","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.semcancer.2019.10.002","article-title":"The potential and controversy of targeting STAT family members in cancer","volume":"60","author":"Verhoeven","year":"2020","journal-title":"Semin. Cancer Biol."},{"issue":"2","key":"10.1016\/j.cellsig.2025.112163_bb0125","doi-asserted-by":"crossref","first-page":"829","DOI":"10.3390\/cancers6020829","article-title":"The multifaceted roles of STAT3 signaling in the progression of prostate cancer","volume":"6","author":"Bishop","year":"2014","journal-title":"Cancers"},{"issue":"2","key":"10.1016\/j.cellsig.2025.112163_bb0130","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1080\/14737159.2019.1665507","article-title":"How else can we approach prostate cancer biomarker discovery?","volume":"20","author":"Drake","year":"2020","journal-title":"Expert. Rev. Mol. Diagn."},{"issue":"5","key":"10.1016\/j.cellsig.2025.112163_bb0135","doi-asserted-by":"crossref","first-page":"287","DOI":"10.2174\/0113892029240239231109082805","article-title":"Identification of plausible candidates in prostate cancer using IntegratedMachine learning approaches","volume":"24","author":"Kour","year":"2023","journal-title":"CG"},{"issue":"1","key":"10.1016\/j.cellsig.2025.112163_bb0140","doi-asserted-by":"crossref","first-page":"61","DOI":"10.2174\/0109298665268943231103114654","article-title":"Novel circular RNA CircUBAP2 drives tumor progression by regulating the miR-143\/TFAP2B Axis in prostate cancer","volume":"31","author":"Lv","year":"2024","journal-title":"PPL"},{"issue":"3","key":"10.1016\/j.cellsig.2025.112163_bb0145","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1158\/0008-5472.CAN-22-2709","article-title":"Protein phosphatase 1 subunit PPP1R14B stabilizes STMN1 to promote progression and paclitaxel resistance in triple-negative breast cancer","volume":"83","author":"Liao","year":"2023","journal-title":"Cancer Res."},{"issue":"8","key":"10.1016\/j.cellsig.2025.112163_bb0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbamcr.2024.119840","article-title":"PPP1R14B-mediated phosphorylation enhances protein stability of RPS6KA1 to promote hepatocellular carcinoma tumorigenesis","volume":"1871","author":"Zhou","year":"2024","journal-title":"Biochim. Biophys. Acta (BBA) - Mol. Cell Res."},{"issue":"12","key":"10.1016\/j.cellsig.2025.112163_bb0155","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.3390\/cancers11122002","article-title":"JAK-STAT signaling: a double-edged sword of immune regulation and cancer progression","volume":"11","author":"Owen","year":"2019","journal-title":"Cancers"},{"issue":"9","key":"10.1016\/j.cellsig.2025.112163_bb0160","doi-asserted-by":"crossref","first-page":"7076","DOI":"10.1074\/jbc.M108255200","article-title":"Activation of the androgen receptor N-terminal domain by Interleukin-6 via MAPK and STAT3 signal transduction pathways","volume":"277","author":"Ueda","year":"2002","journal-title":"J. Biol. Chem."},{"issue":"6","key":"10.1016\/j.cellsig.2025.112163_bb0165","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1158\/1541-7786.MCR-15-0495","article-title":"SOCS3 modulates the response to enzalutamide and is regulated by androgen receptor Signaling and CpG methylation in prostate cancer cells","volume":"14","author":"Handle","year":"2016","journal-title":"Mol. Cancer Res."},{"issue":"2","key":"10.1016\/j.cellsig.2025.112163_bb0170","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1002\/pros.22741","article-title":"Inhibition of constitutively active Stat3 reverses enzalutamide resistance in LNCaP derivative prostate cancer cells","volume":"74","author":"Liu","year":"2014","journal-title":"Prostate"},{"issue":"8","key":"10.1016\/j.cellsig.2025.112163_bb0175","doi-asserted-by":"crossref","first-page":"e3007","DOI":"10.1038\/cddis.2017.417","article-title":"Metformin reverses prostate cancer resistance to enzalutamide by targeting TGF-\u03b21\/STAT3 axis-regulated EMT","volume":"8","author":"Liu","year":"2017","journal-title":"Cell Death Dis."},{"issue":"3","key":"10.1016\/j.cellsig.2025.112163_bb0180","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1002\/(SICI)1097-0045(20000215)42:3<186::AID-PROS4>3.0.CO;2-E","article-title":"STAT3 mediates IL-6-induced neuroendocrine differentiation in prostate cancer cells","volume":"42","author":"Spiotto","year":"2000","journal-title":"Prostate"},{"issue":"30","key":"10.1016\/j.cellsig.2025.112163_bb0185","doi-asserted-by":"crossref","first-page":"20635","DOI":"10.1074\/jbc.M709479200","article-title":"The PIM1 kinase is a critical component of a survival pathway activated by docetaxel and promotes survival of docetaxel-treated prostate cancer cells","volume":"283","author":"Zemskova","year":"2008","journal-title":"J. Biol. Chem."},{"issue":"19","key":"10.1016\/j.cellsig.2025.112163_bb0190","doi-asserted-by":"crossref","first-page":"4854","DOI":"10.3390\/cancers13194854","article-title":"Impact of STAT proteins in tumor progress and therapy resistance in advanced and metastasized prostate cancer","volume":"13","author":"Ebersbach","year":"2021","journal-title":"Cancers"},{"issue":"5","key":"10.1016\/j.cellsig.2025.112163_bb0195","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1158\/1535-7163.MCT-13-0605","article-title":"Pharmacologic suppression of JAK1\/2 by JAK1\/2 inhibitor AZD1480 potently inhibits IL-6\u2013induced experimental prostate cancer metastases formation","volume":"13","author":"Gu","year":"2014","journal-title":"Mol. Cancer Ther."},{"issue":"7","key":"10.1016\/j.cellsig.2025.112163_bb0200","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1634\/theoncologist.2013-0198","article-title":"AZD1480: a phase I study of a novel JAK2 inhibitor in solid tumors","volume":"18","author":"Plimack","year":"2013","journal-title":"Oncologist"},{"issue":"11","key":"10.1016\/j.cellsig.2025.112163_bb0205","doi-asserted-by":"crossref","first-page":"3028","DOI":"10.1158\/1078-0432.CCR-09-3122","article-title":"Clinical and correlative results of SWOG S0354: a phase II trial of CNTO328 (Siltuximab), a monoclonal antibody against Interleukin-6, in chemotherapy-pretreated patients with castration-resistant prostate cancer","volume":"16","author":"Dorff","year":"2010","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.cellsig.2025.112163_bb0210","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.ejca.2011.10.014","article-title":"Randomised phase II study of siltuximab (CNTO 328), an anti-IL-6 monoclonal antibody, in combination with mitoxantrone\/prednisone versus mitoxantrone\/prednisone alone in metastatic castration-resistant prostate cancer","volume":"48","author":"Fizazi","year":"2012","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.cellsig.2025.112163_bb0215","article-title":"Cancer chemoprevention: a strategic approach using phytochemicals","volume":"12","author":"MS","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.cellsig.2025.112163_bb0220","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.jsbmb.2013.12.010","article-title":"Soy isoflavones and prostate cancer: a review of molecular mechanisms","volume":"140","author":"Mahmoud","year":"2014","journal-title":"J. Steroid Biochem. Mol. Biol."},{"issue":"6","key":"10.1016\/j.cellsig.2025.112163_bb0225","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.3390\/molecules24061076","article-title":"Isoflavones","volume":"24","author":"K\u0159\u00ed\u017eov\u00e1","year":"2019","journal-title":"Molecules"},{"key":"10.1016\/j.cellsig.2025.112163_bb0230","first-page":"18","article-title":"Chrysin: a potential antiandrogen ligand to mutated androgen receptors in prostate cancer","author":"Carranza-Aranda","year":"2025","journal-title":"CMP"},{"issue":"1","key":"10.1016\/j.cellsig.2025.112163_bb0235","doi-asserted-by":"crossref","first-page":"249","DOI":"10.3390\/cancers15010249","article-title":"Multifaceted pharmacological potentials of curcumin, genistein, and Tanshinone IIA through proteomic approaches: an in-depth review","volume":"15","author":"Khan","year":"2022","journal-title":"Cancers"},{"issue":"3","key":"10.1016\/j.cellsig.2025.112163_bb0240","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/s41573-020-00114-z","article-title":"Natural products in drug discovery: advances and opportunities","volume":"20","author":"Atanasov","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"issue":"7","key":"10.1016\/j.cellsig.2025.112163_bb0245","doi-asserted-by":"crossref","first-page":"4828","DOI":"10.1074\/jbc.M004894200","article-title":"The plant isoflavenoid genistein activates p53 and Chk2 in an ATM-dependent manner","volume":"276","author":"Ye","year":"2001","journal-title":"J. Biol. Chem."},{"issue":"2","key":"10.1016\/j.cellsig.2025.112163_bb0250","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1207\/S15327914NC330202","article-title":"p53-independent apoptosis induced by genistein in lung cancer cells","volume":"33","author":"Lian","year":"1999","journal-title":"Nutr. Cancer"},{"issue":"11","key":"10.1016\/j.cellsig.2025.112163_bb0255","doi-asserted-by":"crossref","first-page":"12512","DOI":"10.3390\/cimb46110743","article-title":"Effect of soy isoflavone on prostate cancer cell apoptosis through inhibition of STAT3, ERK, and AKT","volume":"46","author":"Lee","year":"2024","journal-title":"CIMB"},{"key":"10.1016\/j.cellsig.2025.112163_bb0260","doi-asserted-by":"crossref","first-page":"431S","DOI":"10.3945\/ajcn.113.071290","article-title":"Genistein inhibits human prostate cancer cell detachment, invasion, and metastasis","volume":"100","author":"Pavese","year":"2014","journal-title":"Am. J. Clin. Nutr."},{"issue":"1","key":"10.1016\/j.cellsig.2025.112163_bb0265","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/1471-2407-8-132","article-title":"Phase II trial of isoflavone in prostate-specific antigen recurrent prostate cancer after previous local therapy","volume":"8","author":"Pendleton","year":"2008","journal-title":"BMC Cancer"},{"issue":"6","key":"10.1016\/j.cellsig.2025.112163_bb0270","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1080\/01635581.2011.582221","article-title":"Efficacy and safety of short-term genistein intervention in patients with localized prostate cancer prior to radical prostatectomy: a randomized, placebo-controlled, double-blind phase 2 clinical trial","volume":"63","author":"Lazarevic","year":"2011","journal-title":"Nutr. Cancer"}],"container-title":["Cellular Signalling"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0898656825005789?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0898656825005789?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T06:48:52Z","timestamp":1781678932000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0898656825005789"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":54,"alternative-id":["S0898656825005789"],"URL":"https:\/\/doi.org\/10.1016\/j.cellsig.2025.112163","relation":{},"ISSN":["0898-6568"],"issn-type":[{"value":"0898-6568","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PPP1R14B promotes the progression of prostate cancer by regulating the JAK2\/STAT3\/AR pathway and alters the sensitivity and resistance to enzalutamide","name":"articletitle","label":"Article Title"},{"value":"Cellular Signalling","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cellsig.2025.112163","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"112163"}}